Topic: Polysaccharide Peptide--Anyone have a clue?
gwb
Frequent Contributor (1K+ posts)
Member # 7273
posted
During a recent conversation I had with an alternative doctor he suggested I look in taking Polysaccharide Peptide. He said that, "One of the molecules that's helping people with spirochetes is Polysaccharide Peptides".
Anyone know anything about this? Has anyone taken it and had good results with it?
I'm very interested in learning more about Polysaccharide Peptides, especially if it's something that can help those of us with lyme.
posted
Quick google search reveals that its extract from mushrooms claimed to have immunomodulatory properties. It might very well work - most immunotherapy is based either on direct introduction of cytokines and other mediating proteins into systems or using foreign substances to stimulate the immune system (immune system recognizes foreign substances -> starts being stimulated)
Though I couldnt find any research proving it
Posts: 856 | From MA | Registered: Jul 2009
| IP: Logged |
Carol in PA
Frequent Contributor (5K+ posts)
Member # 5338
Polysaccharide peptide (PSP) is a protein-bound polysaccharide extracted from the edible mushroom Coriolus versicolor.
PSP is currently in the animal-testing phase of research in many countries for use as an anti-tumor drug. It appears to work as a Biological Response Modifier, enhancing the body's own use of macrophages and T-lymphocytes, rather than directly attacking any tumors.
Coriolus versicolor is also known as Turkey Tail mushroom. When I looked it up at iHerb, there were many good reviews.
I got some a couple weeks ago, and began taking it this last week. I've taken other mushroom extracts before, and haven't really noticed any obvious effects.
So we'll see what happens. Carol
Posts: 6947 | From Lancaster, PA | Registered: Feb 2004
| IP: Logged |
Carol in PA
Frequent Contributor (5K+ posts)
Member # 5338
posted
Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer
Background: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and over 60% of patients present with advanced stages.
Although polysaccharide peptides (PSP), isolated from the fungus Coriolus versicolor, have been reported to have anti-tumor effects, its clinical efficacy has not been properly evaluated.
Methods: Double-blind placebo-controlled randomized study to evaluate the effects of 28-day administration of PSP (Windsor Pharmaceutical, Hong Kong) on patients, who had completed conventional treatment for advanced NSCLC.
Results: Thirty-four patients, with no significant difference in their baseline demographic, clinical or tumor characteristics, or previous treatment regimes, were recruited into each of the PSP and control arms.
After 28-day treatment, there was a significant improvement in blood leukocyte and neutrophil counts, serum IgG and IgM, and percent of body fat among the PSP, but not the control, patients.
Although the evaluable PSP patients did not improve in NSCLC-related symptoms, there were significantly less PSP patients withdrawn due to disease progression, than their control counterparts. (5.9 and 23.5%, respectively)
There was no reported adverse reaction attributable to the trial medications.
Conclusion: PSP treatment appears to be associated with slower deterioration in patients with advanced NSCLC.
The Lyme Disease Network is a non-profit organization funded by individual donations. If you would like to support the Network and the LymeNet system of Web services, please send your donations to:
The
Lyme Disease Network of New Jersey 907 Pebble Creek Court,
Pennington,
NJ08534USA http://www.lymenet.org/
UBBFriend: Email this page to someone!
Printer-friendly view of this topic